
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5580949/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Implementation of large-scale laboratory-based detection of COVID-19 in the Veterans Health Administration, March 2020 – February 2021. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115617.	0.8	0
2	Public health surveillance in the U.S. Department of Veterans Affairs: evaluation of the Praedico surveillance system. BMC Public Health, 2022, 22, 272.	1.2	6
3	Association of secretor status and recent norovirus infection with gut microbiome diversity metrics in a Veterans Affairs population. Open Forum Infectious Diseases, 2022, 9, ofac125.	0.4	0
4	Effectiveness of Messenger RNA–based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. Clinical Infectious Diseases, 2022, 75, 2186-2192.	2.9	12
5	A Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Prediction Model From Standard Laboratory Tests. Clinical Infectious Diseases, 2021, 73, e2901-e2907.	2.9	24
6	From implementation to sustainment: A large-scale adverse event disclosure support program generated through embedded research in the Veterans Health Administration. Healthcare, 2021, 8, 100496.	0.6	3
7	COVID-19–Related Hospitalization Rates and Severe Outcomes Among Veterans From 5 Veterans Affairs Medical Centers: Hospital-Based Surveillance Study. JMIR Public Health and Surveillance, 2021, 7, e24502.	1.2	26
8	Respiratory co-infections with COVID-19 in the Veterans Health Administration, 2020. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115312.	0.8	12
9	Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients. Open Forum Infectious Diseases, 2021, 8, ofab336.	0.4	8
10	Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1294-1299.	9.0	97
11	COVID-19 Infections Among Healthcare Personnel in the United States Veterans Health Administration, March to August, 2020. Journal of Occupational and Environmental Medicine, 2021, 63, 291-295.	0.9	16
12	Adapting the Surveillance Platform for Enteric and Respiratory Infectious Organisms at United States Veterans Affairs Medical Centers (SUPERNOVA) for COVID-19 Among Hospitalized Adults: Surveillance Protocol. Frontiers in Public Health, 2021, 9, 739076.	1.3	3
13	Trends in Incidence of Norovirus-associated Acute Gastroenteritis in 4 Veterans Affairs Medical Center Populations in the United States, 2011–2015. Clinical Infectious Diseases, 2020, 70, 40-48.	2.9	11
14	Validation of Acute Gastroenteritis-related International Classification of Diseases, Clinical Modification Codes in Pediatric and Adult US Populations. Clinical Infectious Diseases, 2020, 70, 2423-2427.	2.9	7
15	Clusters of nontuberculous mycobacteria linked to water sources at three Veterans Affairs medical centers. Infection Control and Hospital Epidemiology, 2020, 41, 320-330.	1.0	8
16	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: AÂnationwide cohort study. PLoS Medicine, 2020, 17, e1003379.	3.9	271
17	Incidence, etiology, and severity of acute gastroenteritis among prospectively enrolled patients in 4 Veterans Affairs hospitals and outpatient centers, 2016–18. Clinical Infectious Diseases, 2020, 73, e2729-e2738.	2.9	16
18	Companion and complementary diagnostics for infectious diseases. Expert Review of Molecular Diagnostics, 2020, 20, 619-636.	1.5	9

#	Article	IF	CITATIONS
19	Risk for In-Hospital Complications Associated with COVID-19 and Influenza — Veterans Health Administration, United States, October 1, 2018–May 31, 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1528-1534.	9.0	113
20	Title is missing!. , 2020, 17, e1003379.		0
21	Title is missing!. , 2020, 17, e1003379.		0
22	Title is missing!. , 2020, 17, e1003379.		0
23	Title is missing!. , 2020, 17, e1003379.		0
24	Treatment for Gulf War Illness (GWI) with KPAX002 (methylphenidate hydrochloride + GWI nutrient) Tj ETQq0 Psychiatric Research, 2019, 118, 14-20.	0 0 rgBT /C 1.5	Overlock 10 T 6
25	Rapid identification of pathogenic bacteria using Raman spectroscopy and deep learning. Nature Communications, 2019, 10, 4927.	5.8	416
26	Carbon monoxide poisoning surveillance in the Veterans Health Administration, 2010–2017. BMC Public Health, 2019, 19, 190.	1.2	6
27	<i>Notes from the Field</i> : Unexplained Dermatologic, Respiratory, and Ophthalmic Symptoms Among Health Care Personnel at a Hospital — West Virginia, November 2017–January 2018. Morbidity and Mortality Weekly Report, 2019, 68, 1006-1007.	9.0	1
28	Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. Value in Health, 2018, 21, 921-930.	0.1	8
29	A joint frailty model provides for risk stratification of human immunodeficiency virus–infected patients based on unobserved heterogeneity. Journal of Clinical Epidemiology, 2018, 98, 16-23.	2.4	2
30	Epidemiology and burden of influenza in the U.S. Department of Veterans Affairs. Influenza and Other Respiratory Viruses, 2018, 12, 293-298.	1.5	6
31	449. Post-Hurricane Maria Surveillance for Infectious Diseases in the Veterans Affairs San Juan Medical Center, Puerto Rico. Open Forum Infectious Diseases, 2018, 5, S168-S169.	0.4	1
32	1648. Incidence of Norovirus and Rotavirus From Multisite Active Surveillance in Veteran's Affairs Hospitals, December 2016–February 2018: Results From the SUPERNOVA Network. Open Forum Infectious Diseases, 2018, 5, S49-S49.	0.4	3
33	2504. Influenza Surveillance and Outbreaks in the US Department of Veterans Affairs (VA): 2017–2018 Season. Open Forum Infectious Diseases, 2018, 5, S752-S753.	0.4	1
34	Zika virus infection in the Veterans Health Administration (VHA), 2015-2016. PLoS Neglected Tropical Diseases, 2018, 12, e0006416.	1.3	10
35	Economically Efficient Hepatitis C Virus Treatment Prioritization Improves Health Outcomes. Medical Decision Making, 2018, 38, 849-865.	1.2	6
36	Impact of IFNL4 -â^†G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals. Diagnostic Microbiology and Infectious Disease, 2018, 92, 34-36.	0.8	4

#	Article	IF	CITATIONS
37	Rationale and design of the Drugâ€Eluting Stents vs Bareâ€Metal Stents in Saphenous Vein Graft Angioplasty (DIVA) Trial. Clinical Cardiology, 2017, 40, 946-954.	0.7	10
38	A review of drug-drug interactions in older HIV-infected patients. Expert Review of Clinical Pharmacology, 2017, 10, 1329-1352.	1.3	17
39	Epidemiologic Review of Veterans Health Administration Patients with Isolation of Nontuberculous Mycobacteria after Cardiopulmonary Bypass Procedures. Infection Control and Hospital Epidemiology, 2017, 38, 1103-1106.	1.0	6
40	Healthcare-associated Legionnaires' disease: Limitations of surveillance definitions and importance of epidemiologic investigation. Journal of Infection Prevention, 2017, 18, 307-310.	0.5	3
41	Enhanced Influenza Surveillance Using Telephone Triage and Electronic Syndromic Surveillance in the Department of Veterans Affairs, 2011-2015. Public Health Reports, 2017, 132, 16S-22S.	1.3	12
42	Identical Strain of Mycobacterium conceptionense Isolated from Patients at 2 Veterans Affairs Medical Centers within the Same Metropolitan Area over a 4 Year Period. Open Forum Infectious Diseases, 2017, 4, S239-S239.	0.4	1
43	Incidence of Norovirus-Associated Acute Gastroenteritis in Four Veteran's Affairs Medical Center Populations in the United States, 2011–2015. Open Forum Infectious Diseases, 2017, 4, S317-S317.	0.4	0
44	Comparative Effectiveness of High-Dose vs. Standard-Dose Influenza Vaccines among Veterans: 2015–2016 and 2016–2017 Seasons. Open Forum Infectious Diseases, 2017, 4, S456-S457.	0.4	1
45	Factors for Hospitalizations and Neurologic Complications in Zika Virus Infection in the Department of Veterans Affairs (VA). Open Forum Infectious Diseases, 2017, 4, S319-S319.	0.4	1
46	Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV. MDM Policy and Practice, 2017, 2, 238146831771644.	0.5	8
47	Genetic Variation in the <i>IL-6</i> and <i>HLA-DQB1</i> Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection. Journal of Immunology Research, 2016, 2016, 1-9.	0.9	7
48	Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerging Infectious Diseases, 2016, 22, 933-935.	2.0	304
49	Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in Non-VA and VA Populations. MDM Policy and Practice, 2016, 1, 238146831667194.	0.5	7
50	Carbapenem-Resistant Enterobacteriaceae and Antimicrobial Usage Within the Veterans Affairs Healthcare System: 2010–2014. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
51	Epidemiologic Review of Department of Veterans Affairs Patients With Isolation of Non-Tuberculous Mycobacteria After Cardiopulmonary Bypass Procedures. Open Forum Infectious Diseases, 2016, 3, .	0.4	Ο
52	Influenza Surveillance in the Department of Veterans Affairs (VA): 2015–2016 Season. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
53	Zika Virus Infection in the Department of Veterans Affairs (VA). Open Forum Infectious Diseases, 2016, 3, .	0.4	0
54	HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. Journal of Virology, 2016, 90, 6058-6070.	1.5	72

#	Article	IF	CITATIONS
55	Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Annals of Internal Medicine, 2016, 165, 10.	2.0	45
56	Epidemiologic Review of Carbapenem-Resistant Enterobacteriaceae, Duodenoscopes, and Endoscopic Ultrasonography in the Department of Veterans Affairs. Infection Control and Hospital Epidemiology, 2016, 37, 725-728.	1.0	1
57	Multifunctional coatings to simultaneously promote osseointegration and prevent infection of orthopaedic implants. Biomaterials, 2016, 84, 301-314.	5.7	541
58	Are current screening protocols for chronic hepatitis B virus infection adequate?. Diagnostic Microbiology and Infectious Disease, 2016, 85, 159-167.	0.8	16
59	Chikungunya Fever Cases Identified in the Veterans Health Administration System, 2014. PLoS Neglected Tropical Diseases, 2016, 10, e0004630.	1.3	18
60	Improving the Value Proposition of Surveillance Tools: Innovative Uses for VA ESSENCE. Online Journal of Public Health Informatics, 2016, 8, .	0.4	1
61	Enhancing Biosurveillance Specificity Using PraedicoTM, A Next Generation Application. Online Journal of Public Health Informatics, 2016, 8, .	0.4	2
62	Reuse of Insulin Pens Among Multiple Patients at 2 Veterans Affairs Medical Centers. Infection Control and Hospital Epidemiology, 2015, 36, 1121-1129.	1.0	0
63	Emergence of Hemagglutinin Mutations During the Course of Influenza Infection. Scientific Reports, 2015, 5, 16178.	1.6	13
64	Acute cardiac injury events â‰ 8 0Âdays after laboratory-confirmed influenza virus infection among U.S. veterans, 2010–2012. BMC Cardiovascular Disorders, 2015, 15, 109.	0.7	58
65	Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment. Journal of Immunology Research, 2015, 2015, 1-8.	0.9	6
66	Evaluation of PraedicoTM, A Next Generation Big Data Biosurveillance Application. Online Journal of Public Health Informatics, 2015, 7, .	0.4	3
67	Risk of Cardiovascular Events Associated With Current Exposure to HIV Antiretroviral Therapies in a US Veteran Population. Clinical Infectious Diseases, 2015, 61, 445-452.	2.9	70
68	Reply to Young et al. Clinical Infectious Diseases, 2015, 61, 1207-1208.	2.9	0
69	Incidence of Medically-Attended Norovirus-Associated Acute Gastroenteritis in Four Veteran's Affairs Medical Center Populations in the United States, 2011-2012. PLoS ONE, 2015, 10, e0126733.	1.1	13
70	The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study. PLoS ONE, 2014, 9, e92606.	1.1	23
71	1292Incidence of norovirus-associated acute gastroenteritis in four Veteran's Affairs Medical Center populations in the United States, 2011-2012. Open Forum Infectious Diseases, 2014, 1, S49-S49.	0.4	0
72	1690Opportunities for Improved Detection and Treatment of Latent Tuberculosis Infection Among Veterans — Western United States, January 2010–July 2013. Open Forum Infectious Diseases, 2014, 1, S452-S452.	0.4	0

#	Article	IF	CITATIONS
73	1064Influenza Infection in the Department of Veterans Affairs (VA): 2013-2014. Open Forum Infectious Diseases, 2014, 1, S312-S312.	0.4	0
74	GBV viremia and clinical events in advanced HIV infection. Journal of Medical Virology, 2014, 86, 426-432.	2.5	14
75	CD4 Counts and Mortality in Virologically Suppressed US Veterans. Journal of the International Association of Providers of AIDS Care, 2014, 13, 120-126.	0.6	2
76	Human pegivirus RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA-containing particles are infectious in vitro. Journal of General Virology, 2014, 95, 1307-1319.	1.3	73
77	Application of a non–amplification-based technology to detect invasive fungal pathogens. Diagnostic Microbiology and Infectious Disease, 2014, 78, 137-140.	0.8	3
78	MicroRNA and hepatitis C virus- challenges in investigation and translation: a review of the literature. Diagnostic Microbiology and Infectious Disease, 2014, 80, 1-12.	0.8	11
79	Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations. Annals of Internal Medicine, 2014, 161, 546.	2.0	77
80	Public Health Practice Is Not Research. American Journal of Public Health, 2014, 104, 596-602.	1.5	20
81	Effect of management strategies and clinical status on costs of care for advanced HIV. American Journal of Managed Care, 2014, 20, e129-37.	0.8	5
82	Health-related Quality of Life Assessment after Antiretroviral Therapy: A Review of the Literature. Drugs, 2013, 73, 651-672.	4.9	76
83	Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 382-391.	0.9	11
84	Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster. Journal of Infectious Diseases, 2013, 208, 559-563.	1.9	36
85	Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review. PLoS ONE, 2013, 8, e59551.	1.1	173
86	Dengue Surveillance in Veterans Affairs Healthcare Facilities, 2007–2010. PLoS Neglected Tropical Diseases, 2013, 7, e2040.	1.3	4
87	Cost-Effectiveness Analysis of Risk-Factor Guided and Birth-Cohort Screening for Chronic Hepatitis C Infection in the United States. PLoS ONE, 2013, 8, e58975.	1.1	61
88	Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infection and Drug Resistance, 2013, 6, 187.	1.1	69
89	Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients. PLoS ONE, 2013, 8, e60387.	1.1	15
90	Combining Surveillance Systems: Effective Merging of U.S. Veteran and Military Health Data. PLoS ONE, 2013, 8, e84077.	1.1	5

#	Article	IF	CITATIONS
91	Characteristics of Veterans Accessing the Veterans Affairs Telephone Triage Who Have Depression or Suicidal Ideation: Opportunities for Intervention. Online Journal of Public Health Informatics, 2013, 5,	0.4	2
92	New Protease Inhibitors for the Treatment of Chronic Hepatitis C. Annals of Internal Medicine, 2012, 156, 279.	2.0	176
93	Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV. Medical Decision Making, 2012, 32, 70-82.	1.2	12
94	Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Research, 2012, 40, e2-e2.	6.5	117
95	Comparative Assessment of Antimicrobial Usage Measures in the Department of Veterans Affairs. Infection Control and Hospital Epidemiology, 2012, 33, 409-411.	1.0	9
96	Results from a Large-Scale Epidemiologic Look-Back Investigation of Improperly Reprocessed Endoscopy Equipment. Infection Control and Hospital Epidemiology, 2012, 33, 649-656.	1.0	30
97	IL28B polymorphism is not associated with HCV protease diversity in patients coâ€infected with HIV and HCV treated with pegylated interferon and ribavirin. Journal of Medical Virology, 2012, 84, 1522-1527.	2.5	2
98	Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. PLoS ONE, 2012, 7, e45176.	1.1	52
99	Outcomes Associated with a Cognitive-Behavioral Chronic Pain Management Program Implemented in Three Public HIV Primary Care Clinics. Journal of Behavioral Health Services and Research, 2012, 39, 158-173.	0.6	38
100	Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCVâ€monoinfection and HIV/HCV oinfection. Journal of Medical Virology, 2012, 84, 431-437.	2.5	13
101	Results from a Large-Scale Epidemiologic Look-Back Investigation of Improperly Reprocessed Endoscopy Equipment. Infection Control and Hospital Epidemiology, 2012, 33, 649-656.	1.0	3
102	Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations. PLoS ONE, 2012, 7, e40514.	1.1	31
103	Diagnosing invasive fungal disease in critically ill patients. Critical Reviews in Microbiology, 2011, 37, 277-312.	2.7	55
104	One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System. International Journal of Infectious Diseases, 2011, 15, e382-e387.	1.5	37
105	Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. PLoS ONE, 2011, 6, e14764.	1.1	16
106	Determinants of the Cost of Health Services Used by Veterans With HIV. Medical Care, 2011, 49, 848-856.	1.1	24
107	Use of dried clinical samples for storing and detecting influenza RNA. Influenza and Other Respiratory Viruses, 2011, 5, 413-417.	1.5	6
108	Clinically Significant Drug Interactions in Younger and Older Human Immunodeficiency Virus–Positive Patients Receiving Antiretroviral Therapy. Pharmacotherapy, 2011, 31, 480-489.	1.2	20

#	Article	IF	CITATIONS
109	Enhanced health event detection and influenza surveillance using a joint Veterans Affairs and Department of Defense biosurveillance application. BMC Medical Informatics and Decision Making, 2011, 11, 56.	1.5	12
110	Interferon combination therapy for HIV/hepatitis C virus coinfection. Immunotherapy, 2011, 3, 1087-1102.	1.0	1
111	Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials. Reviews on Recent Clinical Trials, 2010, 5, 158-173.	0.4	33
112	Integrating Tobacco Cessation Into Mental Health Care for Posttraumatic Stress Disorder <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2010, 304, 2485.	3.8	188
113	Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV coâ€infected patients. Journal of Medical Virology, 2010, 82, 791-798.	2.5	12
114	Impact of Interferonâ€Ribavirin Treatment on Hepatitis C Virus (HCV) Protease Quasispecies Diversity in HIV―and HCV oinfected Patients. Journal of Infectious Diseases, 2010, 202, 889-893.	1.9	9
115	Effect of Home Testing of International Normalized Ratio on Clinical Events. New England Journal of Medicine, 2010, 363, 1608-1620.	13.9	235
116	Maternal-Fetal Pharmacokinetics and Dynamics of a Single Intrapartum Dose of Maraviroc in Rhesus Macaques. Antimicrobial Agents and Chemotherapy, 2010, 54, 4059-4063.	1.4	15
117	Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. International Journal of Infectious Diseases, 2010, 14, e34-e40.	1.5	5
118	Is spinal tuberculosis contagious?. International Journal of Infectious Diseases, 2010, 14, e659-e666.	1.5	70
119	Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 160-166.	0.9	16
120	Effective Detection of the 2009 H1N1 Influenza Pandemic in U.S. Veterans Affairs Medical Centers Using a National Electronic Biosurveillance System. PLoS ONE, 2010, 5, e9533.	1.1	20
121	Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 27-36.	0.9	26
122	Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 631-639.	0.9	44
123	Thrombocytopenia from Combination Treatment with Oseltamivir and Probenecid: Case Report, MedWatch Data Summary, and Review of the Literature. Pharmacotherapy, 2009, 29, 988-992.	1.2	12
124	The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. Quality of Life Research, 2009, 18, 815-824.	1.5	10
125	Novel Targets for Antiretroviral Therapy. Drugs, 2009, 69, 31-50.	4.9	49
126	Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opinion on Drug Safety, 2009, 8, 357-371.	1.0	42

#	Article	IF	CITATIONS
127	Infectious complications in OIF/OEF veterans with traumatic brain injury. Journal of Rehabilitation Research and Development, 2009, 46, 673.	1.6	9
128	Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid. Antimicrobial Agents and Chemotherapy, 2008, 52, 3013-3021.	1.4	56
129	Severe Pneumonia Due to Adenovirus Serotype 14: A New Respiratory Threat?. Clinical Infectious Diseases, 2008, 46, 421-425.	2.9	112
130	Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. Journal of Interferon and Cytokine Research, 2008, 28, 89-100.	0.5	6
131	Frequency of HIV Screening in the Veterans Health Administration: Implications for Early Diagnosis of HIV Infection. AIDS Education and Prevention, 2008, 20, 258-264.	0.6	10
132	HIV infection in the elderly. Clinical Interventions in Aging, 2008, Volume 3, 453-472.	1.3	124
133	Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age. Annals of Internal Medicine, 2008, 148, 889.	2.0	69
134	The Relationship Between HIV Infection and Cardiovascular Disease. Current Cardiology Reviews, 2008, 4, 203-218.	0.6	39
135	The OPTIMA Cohort. , 2008, , 219-238.		Ο
136	A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy. Medical Decision Making, 2007, 27, 789-821.	1.2	28
137	Relationship Between Antiretroviral Prescribing Patterns and Treatment Guidelines in Treatment-Naive HIV-1-Infected US Veterans (1992-2004). Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 20-29.	0.9	28
138	Prevalence of HIV Infection Among Inpatients and Outpatients in Department of Veterans Affairs Health Care Systems: Implications for Screening Programs for HIV. American Journal of Public Health, 2007, 97, 2173-2178.	1.5	37
139	Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy. HIV Clinical Trials, 2007, 8, 293-302.	2.0	2
140	Role of Environmental Surveillance in Determining the Risk of Hospital-Acquired Legionellosis: A National Surveillance Study With Clinical Correlations. Infection Control and Hospital Epidemiology, 2007, 28, 818-824.	1.0	105
141	Darunavir in the Treatment of HIV-1 Infection. Drugs, 2007, 67, 2802-2803.	4.9	2
142	Representational fluency in HIV clinical practice: A model of instructor discourse. Journal of Continuing Education in the Health Professions, 2007, 27, 149-156.	0.4	1
143	siRNA Delivery into Human Tâ€Cells and Primary Cells with Carbon-Nanotube Transporters. Angewandte Chemie - International Edition, 2007, 46, 2023-2027.	7.2	628
144	HIV Testing of At Risk Patients in a Large Integrated Health Care System. Journal of General Internal Medicine, 2007, 22, 315-320.	1.3	22

#	Article	IF	CITATIONS
145	Prevention of shingles by varicella zoster virus vaccination. Expert Review of Vaccines, 2006, 5, 431-443.	2.0	13
146	Utilization and Access to Antiretroviral Genotypic Resistance Testing and Results Within the US Department of Veterans Affairs. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 59-62.	0.9	2
147	The Effect of Diagnosis with HIV Infection on Health-Related Quality of Life. Quality of Life Research, 2006, 15, 69-82.	1.5	50
148	HIVâ€1 Load Quantitation: A 17â€Year Perspective. Journal of Infectious Diseases, 2006, 194, S38-S44.	1.9	20
149	Hepatitis C Virus Protease Gene Diversity in Patients Coinfected with Human Immunodeficiency Virus. Journal of Virology, 2006, 80, 4196-4199.	1.5	11
150	Case files from Stanford University Medical Center: the initial presentation of HIV-1 infectionwhere public and personal health meet. MedGenMed: Medscape General Medicine, 2006, 8, 24.	0.2	1
151	Accuracy, Precision, and Consistency of Expert HIV Type 1 Genotype Interpretation: An International Comparison (The GUESS Study). Clinical Infectious Diseases, 2005, 41, 92-99.	2.9	8
152	Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy. New England Journal of Medicine, 2005, 352, 570-585.	13.9	552
153	Proteomic Analysis of Serum Cytokine Levels in Response to Highly Active Antiretroviral Therapy (HAART). Journal of Proteome Research, 2005, 4, 227-231.	1.8	17
154	Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA). Journal of Clinical Microbiology, 2004, 42, 563-569.	1.8	93
155	An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Contemporary Clinical Trials, 2003, 24, 481-500.	2.0	32
156	Successful management of disseminated nocardia transvalensis infection in a heart transplant recipient after development of sulfonamide resistance: case report and review. Journal of Heart and Lung Transplantation, 2003, 22, 492-497.	0.3	24
157	Impact of Highly Active Antiretroviral Therapy and Immunologic Status on Hepatitis C Virus Quasispecies Diversity in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Journal of Virology, 2003, 77, 1940-1950.	1.5	42
158	Accuracy of the TRUGENE HIV-1 Genotyping Kit. Journal of Clinical Microbiology, 2003, 41, 1586-1593.	1.8	111
159	Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11672-11677.	3.3	172
160	High levels of adherence do not prevent accumulation of HIV drug resistance mutations. Aids, 2003, 17, 1925-1932.	1.0	200
161	HIV-1 RNA and viral load. Clinics in Laboratory Medicine, 2002, 22, 593-610.	0.7	8
162	Multinodular polymyositis in a patient with human immunodeficiency and hepatitis C virus coinfection. Muscle and Nerve, 2001, 24, 433-437.	1.0	7

#	Article	IF	CITATIONS
163	Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. Aids, 2000, 14, 357-366.	1.0	905
164	Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system. Teratology, 2000, 62, 108-114.	1.8	8
165	Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system. , 2000, 62, 108.		1
166	Stability of Plasma Human Immunodeficiency Virus Load in VACUTAINER PPT Plasma Preparation Tubes during Overnight Shipment. Journal of Clinical Microbiology, 2000, 38, 323-326.	1.8	34
167	Decreased Medical Expenditures for Care of HIV-Seropositive Patients. Pharmacoeconomics, 1999, 16, 307-315.	1.7	28
168	HIV quantitation in spiked vaginocervical secretions: lack of non-specific inhibitory factors. Journal of Virological Methods, 1998, 72, 185-195.	1.0	5
169	Human Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing Phenotype. Journal of Infectious Diseases, 1996, 174, 854-857.	1.9	25
170	Detection of Human Immunodeficiency Virus DNA and RNA in Semen by the Polymerase Chain Reaction. Journal of Infectious Diseases, 1991, 164, 769-772.	1.9	174
171	Cerebral Sparganosis: Case Report and Review. Clinical Infectious Diseases, 1991, 13, 155-159.	2.9	51
172	Fulminant Kaposi's sarcoma complicating long-term corticosteroid therapy. American Journal of Medicine, 1987, 83, 787-789.	0.6	27